Jamil Khurram 4
4 · GALECTIN THERAPEUTICS INC · Filed Dec 19, 2025
Insider Transaction Report
Form 4
Jamil Khurram
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-12-17$7.04/sh−4,479$31,532→ 0 total - Exercise/Conversion
Common Stock
2025-12-17$2.20/sh+6,463$14,219→ 6,463 total - Sale
Common Stock
2025-12-17$7.04/sh−6,463$45,500→ 0 total - Exercise/Conversion
Common Stock
2025-12-17$2.50/sh+8,500$21,250→ 8,500 total - Sale
Common Stock
2025-12-17$7.04/sh−8,500$59,840→ 0 total - Exercise/Conversion
Stock option (right to buy)
2025-12-17−6,463→ 102,037 totalExercise: $2.20From: 2025-03-31Exp: 2034-03-20→ Common Stock (6,364 underlying) - Exercise/Conversion
Stock option (right to buy)
2025-12-17−8,500→ 50,000 totalExercise: $2.50From: 2025-07-31Exp: 2034-08-01→ Common Stock (8,500 underlying)
Footnotes (4)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.
- [F2]The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]The options vest as follows: 50,000 on March 11, 2025, with 50,000 scheduled to vest on each of March 11, 2026 and March 11, 2027.
- [F4]The options vest as follows: 25,000 on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025.